仿制药-话题@MedSci

#仿制药#

261篇内容 | 5555人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261454, encodeId=c6001261454fb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=NMPA关于仿制药一致性评价的52个细节答疑, objectType=article, longId=152508, objectId=9db51525084a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db51525084a, replyNumber=0, likeNumber=74, createdTime=2018-11-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db51525084a, moduleTitle=NMPA关于仿制药一致性评价的52个细节答疑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db51525084a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261453, encodeId=e936126145328, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药通过评价仅仅是补考及格，不要让一致性评价结果变味, objectType=article, longId=151663, objectId=ed8415166360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed8415166360, replyNumber=0, likeNumber=63, createdTime=2018-10-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed8415166360, moduleTitle=仿制药通过评价仅仅是补考及格，不要让一致性评价结果变味, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed8415166360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261452, encodeId=181b126145293, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=日本仿制药一致性评价，地震后行业巨大提升, objectType=article, longId=151611, objectId=978715161142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978715161142, replyNumber=0, likeNumber=81, createdTime=2018-10-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978715161142, moduleTitle=日本仿制药一致性评价，地震后行业巨大提升, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978715161142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261451, encodeId=2e70126145176, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药过评后药价暴涨该如何破？, objectType=article, longId=151572, objectId=699b1515e2af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=699b1515e2af, replyNumber=0, likeNumber=56, createdTime=2018-10-23, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=699b1515e2af, moduleTitle=仿制药过评后药价暴涨该如何破？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=699b1515e2af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261450, encodeId=3ebe12614507c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=原研药危机！谈判药、仿制药纳入地方医保, objectType=article, longId=151386, objectId=423615138685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423615138685, replyNumber=0, likeNumber=72, createdTime=2018-10-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423615138685, moduleTitle=原研药危机！谈判药、仿制药纳入地方医保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423615138685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261449, encodeId=f12c12614494e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=天津出台方案，鼓励研发生产仿制药降低患者用药负担, objectType=article, longId=151088, objectId=0ef7151088e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef7151088e6, replyNumber=0, likeNumber=46, createdTime=2018-10-17, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef7151088e6, moduleTitle=天津出台方案，鼓励研发生产仿制药降低患者用药负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ef7151088e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261448, encodeId=634b1261448a3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=江苏鼓励研发临床急需仿制药, objectType=article, longId=151005, objectId=d268151005da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d268151005da, replyNumber=0, likeNumber=56, createdTime=2018-10-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d268151005da, moduleTitle=江苏鼓励研发临床急需仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d268151005da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261447, encodeId=bbf0126144e59, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=世界精神卫生日| 外资垄断抗抑郁药物市场仿制药成长空间巨大, objectType=article, longId=150774, objectId=642c150e7442, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=642c150e7442, replyNumber=0, likeNumber=63, createdTime=2018-10-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=642c150e7442, moduleTitle=世界精神卫生日| 外资垄断抗抑郁药物市场仿制药成长空间巨大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=642c150e7442)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261446, encodeId=b85d126144672, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=碾压原研？过一致性评价仿制药还有这三道坎, objectType=article, longId=150008, objectId=ba4f1500089e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba4f1500089e, replyNumber=0, likeNumber=46, createdTime=2018-10-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba4f1500089e, moduleTitle=碾压原研？过一致性评价仿制药还有这三道坎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba4f1500089e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261445, encodeId=7e22126144513, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=这297个品种，仿制药大面积退出, objectType=article, longId=149118, objectId=4d9f14911870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d9f14911870, replyNumber=0, likeNumber=51, createdTime=2018-09-21, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d9f14911870, moduleTitle=这297个品种，仿制药大面积退出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d9f14911870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261444, encodeId=adaf126144426, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=基药目录调入调出仿制药直面一致性评价大洗牌, objectType=article, longId=148392, objectId=5c491483925c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c491483925c, replyNumber=0, likeNumber=61, createdTime=2018-09-09, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c491483925c, moduleTitle=基药目录调入调出仿制药直面一致性评价大洗牌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c491483925c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261443, encodeId=ec311261443c3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）, objectType=article, longId=148315, objectId=4743148315b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4743148315b5, replyNumber=0, likeNumber=22, createdTime=2018-09-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4743148315b5, moduleTitle=2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4743148315b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261442, encodeId=1313126144252, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药格局将巨变鲶鱼效应激活原研药研发, objectType=article, longId=148209, objectId=3cc8148209f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cc8148209f5, replyNumber=0, likeNumber=0, createdTime=2018-09-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cc8148209f5, moduleTitle=仿制药格局将巨变鲶鱼效应激活原研药研发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cc8148209f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261441, encodeId=96141261441db, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=全球很大仿制药公司裁员潮变成“喜事” 赛道转换你准备好了吗？, objectType=article, longId=147817, objectId=e93914e817f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e93914e817f9, replyNumber=0, likeNumber=81, createdTime=2018-09-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e93914e817f9, moduleTitle=全球很大仿制药公司裁员潮变成“喜事” 赛道转换你准备好了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e93914e817f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261440, encodeId=89fa1261440f5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=福建仿制药企享税收优惠, objectType=article, longId=147442, objectId=053814e442bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053814e442bd, replyNumber=0, likeNumber=60, createdTime=2018-08-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053814e442bd, moduleTitle=福建仿制药企享税收优惠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053814e442bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261439, encodeId=e39212614394d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=美药管局因抗过敏药价格太高，批准引入肾上腺素笔仿制药, objectType=article, longId=146909, objectId=64c014690988, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64c014690988, replyNumber=0, likeNumber=74, createdTime=2018-08-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64c014690988, moduleTitle=美药管局因抗过敏药价格太高，批准引入肾上腺素笔仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64c014690988)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261438, encodeId=f9e4126143878, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=在仿制药大国印度每年竟有3800万人因药致贫, objectType=article, longId=146831, objectId=3a5f14683145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a5f14683145, replyNumber=0, likeNumber=80, createdTime=2018-08-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a5f14683145, moduleTitle=在仿制药大国印度每年竟有3800万人因药致贫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a5f14683145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261437, encodeId=292b126143e5e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=面对ED：原研药和仿制药该如何选择, objectType=article, longId=146798, objectId=9c2c146e988d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2c146e988d, replyNumber=0, likeNumber=59, createdTime=2018-08-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2c146e988d, moduleTitle=面对ED：原研药和仿制药该如何选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2c146e988d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261436, encodeId=9ec31261436eb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药，又获一省重大支持, objectType=article, longId=146578, objectId=ffba1465e8f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffba1465e8f0, replyNumber=0, likeNumber=53, createdTime=2018-08-15, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffba1465e8f0, moduleTitle=仿制药，又获一省重大支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffba1465e8f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261435, encodeId=bea21261435df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=陕西鼓励研发仿制药为患者减负, objectType=article, longId=146260, objectId=30b114626037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30b114626037, replyNumber=0, likeNumber=82, createdTime=2018-08-11, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30b114626037, moduleTitle=陕西鼓励研发仿制药为患者减负, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30b114626037)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

NMPA关于仿制药一致性评价的52个细节答疑

2018-11-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药通过评价仅仅是补考及格，不要让一致性评价结果变味

2018-10-24

drwjr (审核中...)

前往app查看评论内容

#仿制药#

日本仿制药一致性评价，地震后行业巨大提升

2018-10-24

医者仁心 (审核中...)

前往app查看评论内容

#仿制药#

仿制药过评后药价暴涨该如何破？

2018-10-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

原研药危机！谈判药、仿制药纳入地方医保

2018-10-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

天津出台方案，鼓励研发生产仿制药降低患者用药负担

2018-10-17

drwjr (审核中...)

前往app查看评论内容

#仿制药#

江苏鼓励研发临床急需仿制药

2018-10-16

drwjr (审核中...)

前往app查看评论内容

#仿制药#

世界精神卫生日| 外资垄断抗抑郁药物市场仿制药成长空间巨大

2018-10-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

碾压原研？过一致性评价仿制药还有这三道坎

2018-10-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

这297个品种，仿制药大面积退出

2018-09-21

drwjr (审核中...)

前往app查看评论内容

#仿制药#

基药目录调入调出仿制药直面一致性评价大洗牌

2018-09-09

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）

2018-09-07

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药格局将巨变鲶鱼效应激活原研药研发

2018-09-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

全球很大仿制药公司裁员潮变成“喜事” 赛道转换你准备好了吗？

2018-09-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

福建仿制药企享税收优惠

2018-08-27

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

美药管局因抗过敏药价格太高，批准引入肾上腺素笔仿制药

2018-08-19

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

在仿制药大国印度每年竟有3800万人因药致贫

2018-08-18

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

面对ED：原研药和仿制药该如何选择

2018-08-18

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

仿制药，又获一省重大支持

2018-08-15

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

陕西鼓励研发仿制药为患者减负

2018-08-11

科室
- - 订阅+
  - 更多科室
工具
服务